الفهرس 
Social distributionOnly 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
Minimizing cardiotoxicity of adriamycin used in treatment of leukemia is of particular importance, especially in children who may survive for decades after successful antineoplastic treatment. The aim of therapy now is, not only to add years to life, but also to add quality to these years. This involves many strategies that aim at reduction of cardiotoxicity either by dose modification, longer infusion time, use of less cardiotoxic anthracyclines or the combined therapy with medications such as vitamins A, C and E, and antioxidants. Carvedilol, a nonselective ~-adrenergic blocking agent with a 1- blocking activity, has a potent antioxidant effect with a lO-fold greater activity than vitamin E. Moreover, some carvedilol metabolites found in plasma also exhibit antioxidative activity approximately 50-100 fold greater than carvedilol. These unique properties of carvedilol may be important in preventing progressive deterioration of left ventricular dysfunction and chronic heart failure in adriamycin induced cardiomyopathy.